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ABSTRACT 
Multiple myeloma is a disease typical of the elderly, and, because of the increase in life expectancy 
of the general population, its incidence is expected to grow in the future. Elderly patients represent 
a particular challenge due to their marked heterogeneity. Many new and highly effective drugs have 
been introduced in the last few years, and results from clinical trials are promising. Besides the 
availability of novel agents, a careful evaluation of elderly patients showed to be a key factor for the 
success of therapy. A geriatric assessment is a valid strategy to better stratify patients. In particular, 
different scores are available today to appropriately assess elderly patients and define their 
fitness/frailty status. The choice of treatment – transplantation, triplets, doublets, or reduced-dose 
therapies including novel agents – should depend on the patient’s fitness status (fit, intermediate-fit 
or frail). Second-generation novel agents have also been evaluated as salvage therapy in the elderly, 
and these new agents certainly represent a further step forward in the treatment armamentarium for 
elderly patients with multiple myeloma.  
 
 
INTRODUCTION 
The incidence of Multiple Myeloma (MM) is strongly related to age: approximately 70% of MM 
diagnoses occur in patients older than 65 years and 40% in those older than 75 years.1 Since the 
worldwide population is rapidly ageing, the number of elderly people is considerably increasing, with 
those older than 80 years projected to amplify from 137 million in 2017 to 425 million in 2050.2 As 
the prevalence of cancer including MM will increase, this urges us to designate therapies, including 
clinical trials, for elderly cohorts. 
Due to first-generation novel agents, namely bortezomib, thalidomide and lenalidomide, progression-
free survival (PFS) and overall survival (OS) have substantially improved in MM. Before 2000, the 
median OS in newly diagnosed MM (NDMM) was ~2.5 years, whereas this is now more than 5 years, 
depending on the risk and response status of patients.3,4 Such a remarkable survival improvement 
is now also evident in the elderly population.  In fact, after 2000, 6-year OS of patients over 65 years 
significantly improved from 35% to 56% (p<0.001).4 Nevertheless, older people represent a 
heterogeneous population in terms of both physical and psycho-social functioning. In addition, it is 
now accepted that chronological and biological age may not correspond, and that the presence of 
frailty, comorbidities and disabilities can affect therapy endurance. Thus, the assessment of frailty is 
desirable, but sensitive tools need to be systematically tested and validated clinically. Moreover, 
therapy allocation and randomized studies are not yet tailored according to patients' frailty status. 
Of note, MM patients ≥75 years treated upfront with novel agents may show similar PFS as 
compared with younger patients, although their OS is impaired. This is partially due to the fact that 
toxic side effects from first-line treatment may preclude second-line treatment, with third-line 
therapies in >80-year old MM patients being extremely rare.5 Therefore, it is essential to identify 
patients that may need specifically tailored strategies to optimize tolerability and efficacy of the 
different treatment lines.6  
Recently, second-generation proteasome inhibitors (PIs), immunomodulatory drugs (IMIDs) and 
monoclonal antibodies (moAb) have led to the development of multi-drug salvage combinations. In 
this context, the impacts of age and frailty have not been fully determined. Therefore, this paper aims 
to provide recommendations from the European Myeloma Network (EMN) on the management of 
elderly MM patients in the era of innovative agents. 
 
 
METHODS 
An interdisciplinary panel of myeloma experts on behalf of the EMN evaluated randomized clinical 
studies, meta-analyses, systematic reviews and other clinical analyses on the treatment of elderly 
MM patients published until December 2017. The Grading of Recommendations Assessment 
Development and Evaluation (GRADE) system was used to assign grades of recommendations 
(Suppl. Table 1).7 If no sufficient data were available, the expert panel reached a consensus after 
internal discussion and provided recommendations. Initial discussion took place at the 8th EMN 
Trialist meeting (Baveno, Italy, 25th-26th September 2016) and finalization of this paper during and 
after the 9th EMN meeting (24th-25th September 2017). The recommendations circulated among EMN 
panel members. The manuscript subsequently underwent revision until all EMN panel experts 
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reached mutual consensus and it is published as a consensus paper by the European Hematology 
Association (EHA). 
 
 
TREATMENT OF ELDERLY PATIENTS WITH NEWLY DIAGNOSED MM (NDMM) 
Six prospective randomized trials compared melphalan and prednisone alone (MP) with MP plus 
thalidomide (MPT) showing a significant improvement in PFS with MPT, while conflicting results 
were reported for OS. Although the trials differed in terms of patient characteristics and MP/MPT-
schedules, a meta-analysis of all 1685 patients showed a significant benefit for MPT in terms of OS 
(HR 0.83, 95% CI 0.73–0.94, p=0.004), which increased from 32.7 with MP to 39.3 months with 
MPT. Consistently, MPT was associated with superior PFS (20.3 months with MPT vs. 14.9 months 
with MP; HR 0.68, 95% CI 0.61–0.76, p<0.0001). Nevertheless, a higher cumulative incidence of 
grade 3-4 hematologic and non-hematologic toxicities was documented with MPT, leading to a 
toxicity-related discontinuation of thalidomide in 35% of MPT patients, with peripheral neuropathy 
(PNP) being the main reason (15%).8,9  
The combination bortezomib-melphalan-prednisone (VMP) was introduced as another standard 
upfront combination: VMP (intravenous bortezomib twice-weekly for cycles 1-4 and once-weekly for 
cycles 5-9) showed to be superior to MP in terms of PFS (median: 21.7 vs. 15.2 months, respectively; 
HR 0.558; P<0.001)10 in the VISTA trial. Furthermore, after a median follow-up of 60.1 months, a 
31% reduced risk of death was achieved with VMP vs. MP (median OS: 56.4 vs. 43.1 months; HR, 
0.695; P<0.001).11 The survival benefit with VMP was found across pre-specified patient subgroups 
including age ≥75 years, ISS stage III, and creatinine clearance <60mL/min. The occurrence of PNP 
negatively affected long-term bortezomib use. However, once-weekly rather than twice-weekly 
dosing, subcutaneous rather than intravenous route, and prompt dose reductions are current 
effective strategies to significantly reduce bortezomib-induced PNP, without affecting efficacy.12,13 
Furthermore, VMP could partly restore PFS in high-risk patients, leading to a non-statistically 
different PFS in high-risk vs. standard-risk cytogenetics, although numbers were low.10  
In the FIRST trial, continuous treatment with lenalidomide and dexamethasone (Rd) significantly 
improved PFS compared to fixed duration MPT for 12 cycles or Rd for 18 cycles (Rd 18).14 Indeed, 
continuous Rd significantly reduced the risk of progression compared to MPT (HR 0.69; p<0.00001) 
and Rd 18 (HR 0.70), whereas no significant PFS difference between Rd 18 and MPT was 
determined. Median PFS with continuous Rd, Rd 18 and MPT was 26, 21 and 21.9 months, 
respectively. The PFS benefit of continuous Rd vs MPT was confirmed in various subgroups, 
including age, ISS stage and ECOG PS, but not with increased lactate dehydrogenase (LDH), high-
risk cytogenetics or severe reduction in renal function (creatinine clearance <30 ml/min). Continuous 
Rd was associated with fewer hematologic and neurologic AEs (grade 3-4 PNP 1% vs 9%), a 
moderate increase in infections (grade 3-4: 29% vs 17%) and fewer second primary hematologic 
cancers as compared with MPT.  
To test the feasibility and activity of these 2 efficient regimens at diagnosis, the Spanish group 
evaluated both VMP and Rd regimens in 2 different schemes: 9 cycles of VMP (intravenous 
bortezomib twice-weekly for cycle 1 and once-weekly for cycle 2-9) followed by 9 cycles of Rd 
(sequential scheme) vs. VMP directly followed by Rd in an alternate fashion for up to 18 cycles 
(alternating scheme).15 Both arms induced similar median PFS (32 vs. 34 months, p=0.65) and 3-
year OS (72% vs. 74%, respectively p=0.63). The greatest benefit of this approach was observed in 
patients aged 65 to 75 years. Moreover, the sequential and alternating groups showed similar 
hematologic and non-hematologic toxicity. However, since this PETHEMA trial did not directly 
compare VMP with Rd, the superiority of one regimen over the other and/or preference in different 
subgroups remained unanswered. 
Recently, the CLARION study evaluated the combination of carfilzomib with melphalan-prednisone 
(KMP) vs. standard VMP for 9 cycles, showing comparable PFS (22.3 vs. 22.1 months, HR, 0.91; 
95% CI, 0.75–1.10). Median time-to-progression (TTP) was 27.5 vs. 23.5 months (HR 0.84; 0.68–
1.04, p=0.05), and median OS was not reached in both arms (HR 1.08; 95% CI, 0.82–1.43). Grade 
≥3 hypertension, dyspnea, acute renal failure and cardiac failure were higher in the KMP vs. VMP 
group. Moreover, KMP showed a slightly higher incidence of treatment discontinuation (17.5% vs. 
15.5%) due to adverse events (AEs) and deaths (6.5% vs. 4.3%).16 The failure of KMP to improve 
outcome may be due to a lower PNP rate with VMP than expected, thus prolonging VMP therapy; 
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melphalan being used as a less suitable combination partner; and lesser endurance of twice weekly 
carfilzomib treatment in elderly patients, leading to a slightly higher frequency of AEs. 
Moreover, to further improve response and outcome, the role of intravenous bortezomib combined 
with lenalidomide-dexamethasone (VRd) vs. Rd in NDMM patients was evaluated in the phase 3 
SWOG-S0777 study.17 That study included both younger and elderly patients (≥65 years: 43%), 
stratified according to the intent to transplant. Median PFS was significantly improved in the VRd vs. 
Rd group (43 vs. 30 months, respectively; HR 0.712, 96% CI 0.56-0.906; p=0.0018). Median OS 
was also improved in the VRd vs. Rd group (75 vs. 64 months, respectively, HR 0.709, 95% CI 
0.524-0.959; p=0.025). Survival was unchanged when patients off study (with intent for ASCT) were 
censored. The advantage of VRd over Rd remained significant for both PFS and OS in an age-
adjusted multivariate analysis (age ≥65). Grade ≥3 toxicities were reported in 82% with VRd and 
75% with Rd, and discontinuation rate due to toxicity was 23% with VRd vs. 10% with Rd. No 
treatment-related deaths occurred in the Rd group, while 2 were reported in the VRd group. 
Therefore, VRd significantly improved PFS and OS with an acceptable risk profile.  
Recently, in the Alcyone trial, the anti-CD38 monoclonal antibody daratumumab combined with   
VMP (subcutaneous bortezomib twice-weekly for cycle 1 and once-weekly for cycles 2-9) followed 
by daratumumab maintenance significantly improved PFS compared to VMP alone (HR 0.50; 95% 
CI 0.38-0.65; p<0.001) after a median follow-up of 16.5 months. The advantage was evident in 
patients with renal impairment, age ≥ 75 years, ISS stage III or high-risk cytogenetics. Adverse 
events included infusion-related reactions in 28% of daratumumab-treated patients (grade 3-4: 4%) 
and infections (grade ≥3: 23% vs 15%) with daratumumab-VMP compared with VMP, although 
treatment discontinuation due to infections was low in both arms (0.9% and 1.4%, respectively).18 
Safety and efficacy results of these trials are summarized in Table 1. 
 
CONTINUOUS TREATMENT 
The goal of maintenance treatment is to maintain or improve the depth and quality of response 
achieved during induction treatment in order to prolong PFS and ultimately OS. Nevertheless, a 
major concern is drug-related toxicity that may limit the long-term use of maintenance and affect 
patients' quality of life (QoL). 
In a phase 3 trial melphalan–prednisone–lenalidomide induction followed by lenalidomide 
maintenance (MPR-R) was compared with melphalan–prednisone–lenalidomide (MPR) or MP-
placebo. Median PFS was significantly longer with MPR-R (31 months) than with MPR (14 months; 
HR 0.49; p<0.001) or MP (13 months; HR 0.40; p<0.001).19 No significant difference in OS was 
reported between treatment arms. The PFS benefit associated with MPR-R was seen in patients 65-
75 years of age, but not in those older than that. After induction, a landmark analysis showed a 66% 
reduction in the rate of progression with MPR-R (HR for the comparison with MPR: 0.34; p<0.001) 
that was age-independent. Second primary malignancies (SPMs) were increased in the 
lenalidomide-arms: 3-year SPM rate was 7% with MPR-R or MPR vs. 3% with MP. Nevertheless, 
the benefit associated with MPR-R was judged to outweigh the increased risk of SPMs. 
In another phase 3 trial, MPR-R was not significantly superior over melphalan-prednisone-
thalidomide followed by thalidomide maintenance (MPT-T) in terms of PFS (HR, 0.84; p= 0.06) or 
OS (HR, 0.79; p=0.06).20 Moreover, MPT-T induced a significantly higher PNP and MPR-R was 
associated with higher myelosuppression.  Similar data were reported in a previous trial, where the 
use of MPT-T or MPR-R in elderly patients with untreated MM demonstrated no statistical or clinically 
relevant difference in response rates, PFS and OS; however, improved QoL and lower toxicity were 
reported with MPR-R.21 
In the FIRST trial, continuous Rd improved clinically relevant health-related QoL (HRQoL) 
measurements as compared to MPT.22 HRQoL improved with treatment and was generally 
maintained while subjects were progression-free; however, these QoL results were influenced by 
the fact that only patients responding and staying on treatment were included in subsequent 
analyses. As expected, progressive disease was associated with worsening HRQoL across all 
evaluated domains, and MPT was associated with worse treatment-induced side effects as 
compared with Rd. Median OS was longer with continuous Rd than with MPT (59.1 vs 49.1 months; 
HR 0.78), including a 14-month difference in patients >75 years.23 However, median OS with 
continuous Rd was comparable to Rd 18 arm (59.1 vs 62.3 months; HR 1.02). Continuous Rd 
prolonged PFS compared with MPT and Rd18 in patients with standard-risk cytogenetics, whereas 
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no statistical difference was found in patients with high-risk cytogenetics; yet patients with high-risk 
cytogenetics did not experience OS benefits with continuous Rd vs MPT.23 Furthermore, continuous 
Rd extended time-to-next-treatment (TTNT) compared with Rd18 and MPT, particularly in patients 
who achieved complete response (CR) or very good partial response (VGPR) (69.5 vs. 39.9 vs 37.7 
months, HR 0.47 for continuous Rd vs Rd18, HR 0.42 for continuous Rd vs MPT). Rates of grade 3-
4 AEs with continuous Rd were similar for patients ≤ or >75 years old; however, older patients 
required lenalidomide dose-reductions more frequently.24 
The Myeloma XI study explored the role of lenalidomide maintenance in both transplant-eligible and 
ineligible patients.25 Lenalidomide maintenance reduced the risk of progression or death by 54% as 
compared with no maintenance (median PFS: 39 vs. 20 months, respectively, HR: 0.46, p<0.0001). 
The PFS benefit persisted across risk subgroups and was independent of induction, response and 
cytogenetic risk groups. For transplant-ineligible patients, median PFS was 26 vs. 11 months, 
respectively (HR 0.44, p<0.0001). At a median follow-up of 30.6 months no difference in OS between 
lenalidomide maintenance vs no maintenance was observed in transplant-ineligible patients (50.8 
vs 57.8 months, HR 1.02). Lenalidomide maintenance improved OS irrespective of cytogenetic risk 
in transplant-eligible patients, but there was no benefit in transplant-ineligible patients.   
The GIMEMA group compared VMP-thalidomide followed by continuous VT (VMPT-VT) with VMP. 
After a median follow-up of 54 months, median PFS was significantly longer with VMPT-VT than with 
VMP (35.3 vs. 24.8 months; respectively; HR 0.58; P<0.001) and the 5-year OS was greater (61% 
vs. 51%; HR 0.70; P<0.01). High-risk and standard-risk cytogenetic patients in both arms had similar 
outcome. Nevertheless, the absence of a second randomization after induction made the 
maintenance vs. no maintenance comparison challenging.26 
The PETHEMA trial compared VMP with bortezomib/thalidomide/prednisone (VTP) followed by 
maintenance with bortezomib/thalidomide (VT) or bortezomib/prednisone (VP): PFS from the start 
of maintenance was 32 months for patients receiving VT and 24 months for those receiving VP (HR 
1.4, 95% CI 0.8–2.1; p=0.1), without a difference in OS (HR 1.2, 0.6–2.4), albeit side effects, 
especially arrhythmia and cardiac events were more prominent with VT than VP.27  
 
GERIATRIC ASSESSMENT (GA) 
Age and PS are the most frequently used criteria to select patients for standard full-dose therapy, 
but the final decision is generally left to the physician’s clinical judgment.28 Indeed, these parameters 
may not be sufficient to describe the heterogeneity of elderly patients, and a large body of geriatric 
literature tries to address this challenge by designing specific geriatric scores. 
Comprehensive29 GA is a procedure developed by geriatricians to evaluate patients’ functional and 
global health status, to identify and manage age-related problems allowing clinicians to select 
therapy appropriately, avoiding over- and undertreatment,30 thus allowing categorization of patients 
into groups with different age-related conditions and risks of toxicity/drop-out. However, full GA is a 
time- and manpower-consuming procedure, and it is challenging to perform in everyday clinical 
practice; thus, more feasible approaches including a limited number of indicators have been 
proposed (Table 2). 
In 2015, the IMWG developed an effective method to detect and grade the severity of frailty. An 
additive scoring system (range 0-5), based on age, comorbidities and functional conditions 
(evaluated with Charlson Comorbidity Index [CCI], Activities of Daily Living [ADL] and Instrumental 
Activities of Daily Living [IADL]), was developed to identify 3 groups of MM patients at diagnosis: fit 
(score=0, 39%); intermediate (score=1, 31%), and frail patients (score≥2, 30%).31 This IMWG-frailty 
index predicted mortality and PFS in elderly patients. The prognostic impact of the frailty profile on 
OS was independent from ISS stage, chromosomal abnormalities, type of treatment and PS in 
multivariate analysis. Grade 3 or higher non-hematologic toxicity and treatment discontinuation due 
to toxicity were also higher in frail patients. To help users, the IMWG score is available online 
(http://www.myelomafrailtyscorecalculator.net/). 
This IMWG-frailty index was prospectively validated and compared with the revised myeloma 
comorbidity index (R-MCI) in a German cohort of NDMM patients.32 This validation demonstrated a 
3-year-OS of 91%, 77% and 47% for fit, intermediate-fit and frail patients, respectively. Using the 
CCI, Hematopoietic Cell Transplant-Co-morbidity Index (HCT-CI), Kaplan-Feinstein Index (KFI) and 
R-MCI also allowed to define fit and frail patients with distinct PFS and OS, albeit most pronounced 
differences resulted via R-MCI and IMWG-frailty index. Moreover, the relevance of the R-MCI was 
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demonstrated in 801 consecutive German MM patients, this cohort being examined also 
prospectively within a training and validation set. Multivariate analysis determined 5 risk factors 
(renal-, lung-, KPS-impairment, frailty, age) as highly significant for OS. These were combined in the 
weighted R-MCI, allowing identification of fit (R-MCI 1-3), intermediate-fit (R-MCI 4-6) and frail 
patients (R-MCI 7-9): these subgroups showed median OS rates of 10.1, 4.4 and 1.2 years, 
respectively. The R-MCI was again compared to the CCI, HCT-CI and KFI: if each were divided in 
risk groups, highest HRs, best prediction and Brier scores were achieved with the R-MCI. 
Advantages of the R-MCI included its prospective validity, accurate assessment of patients' physical 
conditions, score-robustness due to repeated test- and validation analyses and its simple clinical 
applicability. To expedite its use, a web-based application was implemented 
(www.myelomacomorbidityindex.org) (Table 2). 
The IMWG-frailty index was also validated in the FIRST-trial. However, ADL and IADL were not 
available, instead the EQ5D was used. Results confirmed an inferior outcome in frail vs. fit patients, 
with median PFS of 20.3 vs. 43.7 months and median OS of 52.3 months vs. not reached, 
respectively.33 
Moreover, the N-terminal natriuretic peptide type B (NT-proBNP) was used as a laboratory risk 
parameter and predictor of survival independent of age and PS in another large group of NDMM 
patients, it was therefore proposed as an additive biomarker of frailty (Table 2).34 Other biomarkers 
of frailty (such as sarcopenia, which predicts outcomes in patients with solid tumors) are under 
evaluation.35 
The use of standardized minimum datasets of tools and biomarkers to define frailty is an advantage 
to permit comparisons between different studies. More efficient methods are under development. 
Clinical trials designed for tailored treatment according to frailty status are ongoing. Preliminary 
analyses from a Dutch-HOVON study support the prognostic value of the IMWG-frailty index; 
prospective use of the R-MCI is also ongoing in and outside clinical trial MM patients. Objectively 
measured tests (gait speed and handgrip strength) and biomarkers, (senescence marker and 
sarcopenia), are therein investigated. In the ongoing German prospective studies, comorbidity 
scores and defined functional fitness tests are combined to determine most powerful frailty tools for 
MM, for effective treatment and toxicity-avoidance.36 
 
 
Recommendations. Both IMWG-frailty index and R-MCI are recommended instruments to identify 
fit, intermediate and frail patients, the latter showing an inferior outcome and a higher treatment 
discontinuation rate (1B). 
Fit, elderly patients may receive full-dose therapy, including VMP (grade 1A), Rd (1A) or VRD (2B). 
Solid data recently published on the addition of the monoclonal antibody daratumumab to VMP will 
probably change the scenario in the near future. Patients with intermediate-fitness can benefit from 
doublets and/or even low-dose triplets (2C), whereas frail patients may require doublet treatment at 
lower doses (2C) (Table 3). Bortezomib-based induction may be preferred in patients with impaired 
renal function. Once-weekly subcutaneous bortezomib schedule may be applied due to the lower 
AE incidence. Rd may be preferred, if oral administration and lack of inducing or aggravating PNP 
are major considerations. 
In transplant-ineligible patients, continuous lenalidomide treatment (e.g. Rd) prolongs PFS (1A). 
Continuous Rd does not produce an OS advantage vs fixed duration Rd but prolongs TTNT, 
especially in patients achieving a high-quality response (at least VGPR).  
Baseline cytogenetic data should be obtained in all elderly MM patients in whom a palliative 
approach is not planned. In the presence of high-risk cytogenetics, bortezomib-based treatment may 
be beneficial (2C), but confirmatory, well-designed trials are lacking.37 Continuous treatment with 
lenalidomide remains uncertain in patients with high-risk cytogenetics and still needs to be 
confirmed.  
 
AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) 
The benefit of high-dose therapy and ASCT in older patients has been controversially discussed.38 
Several retrospective single-center and transplant-registry analyses demonstrated that ASCT is 
possible in elderly and fit MM patients.39–42 However, patients undergoing ASCT need particular 
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attention and should meet strict selection criteria,43–45 at best via comorbidity tests, which take into 
account biological rather than chronological age.31,32,46–49 
Tandem-ASCT and even full-dose melphalan (Mel) 200mg/m2-conditioning are possible in elderly-
fit patients; the DSMM XIII study is assessing continuous Rd treatment vs. Rd induction, tandem 
melphalan 140 mg/m2-ASCT consolidation and lenalidomide maintenance in 60-75 year-old MM 
patients, and long-term results are eagerly awaited.50  
Especially in patients aged >70 years, the risk of toxicities may counteract the potential benefits of 
ASCT. In a phase 2 study, bortezomib-pegylated liposomal doxorubicin-dexamethasone (PAD) 
induction, followed by melphalan 100 mg/m2 and ASCT, lenalidomide-prednisone consolidation and 
lenalidomide maintenance was highly effective (median PFS: 48 months; 5-year OS: 63%).51 
However, for patients >70 years a significantly higher rate of treatment-related AEs was observed in 
comparison with younger patients (19% vs. 5%).  
Recently, criteria for patient selection and melphalan dose-reduction in the elderly have been 
proposed by the EMN.38 However, future trials are needed to define selection criteria and potential 
benefit for ASCT as compared with innovative combinations including IMiDs plus PIs and monoclonal 
antibodies. 
 
Recommendations: MM patients without prohibitive comorbidities and adequate organ function, 
thus transplant-eligible, may benefit from high-dose melphalan followed by ASCT (1A). In fit or 
intermediate-fit (rather than frail) patients up to the age of 70 (or even 75 years), ASCT with 
melphalan conditioning 140-200 mg/m2 is feasible, and the selection of suitable patients should at 
best be performed via comorbidity tests (2C).38  
Lenalidomide maintenance after ASCT prolongs PFS and OS in younger patients. Although phase 
3 trials in the elderly are lacking, maintenance therapy after ASCT is advisable (2C). 
 
 
 
HOW TO SELECT AND CHOOSE TREATMENT 
The achievement of CR52 and minimal residual disease (MRD)53 negativity is a relevant endpoint of 
MM treatment. However, an optimal balance between treatment efficacy and toxicity is of utmost 
importance. Yet, standard treatment may induce a higher rate of AEs, translating into a higher 
discontinuation rate and an inferior survival benefit, particularly in frail patients.54,55  
The assessment of fitness and frailty can thus be used to determine the treatment goals and select 
the most appropriate option. In fit patients, the priority of treatment should be the efficacy and the 
goal of therapy is the achievement of a deep remission (CR or MRD negativity). In intermediate 
patients, the priority of treatment should be a balance between efficacy and safety and the goal is 
the achievement of a deep response while maintaining a good safety profile. In frail patients, the 
priority of treatment should be to not harm but to preserve QoL by lowering toxicity (Table 3).Two 
independent trials demonstrated that triplets did not offer an advantage over doublet combinations, 
especially in frail patients.56,57 The community-based, phase 3 UPFRONT trial compared three 
frontline bortezomib-containing regimens in transplant-ineligible patients (42% of the patients were 
aged≥75 years, and 18% were aged ≥80 years).57 After a median follow-up of 42.7 months, median 
PFS and OS with VD, VTD or VMP were 14.7, 15.4 and 17.3 months and 49.8, 51.5 and 53.1 months, 
respectively, with no significant differences among treatments (global p=0.46 and p=0.79, 
respectively). AEs were more common with VTD than VD or VMP. Bortezomib maintenance was 
feasible without producing cumulative toxicity. In another trial including 25% of frail patients, the 
triplet lenalidomide-based regimens (MPR, CPR) did not induce any advantage over doublet Rd, 
which was associated with the lowest toxicity in elderly frail patients.56,58   
Suggested frailty-adjusted dose reduction in patients with MM using standard and novel agents can 
be considered (Table 4). 
 
 
TREATMENT OF RELAPSED/REFRACTORY ELDERLY MM PATIENTS  
Treatment of elderly MM patients at relapse is often challenging, in part due to the fact that the 
number of therapeutic lines that can be endured is limited compared to younger and fitter patients.59 
Advanced age, coexisting comorbidities, toxicities from previous therapies and an aggressive pattern 
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of relapse may also reduce the spectrum of feasible salvage therapies.6 The analysis of the 
risk/benefit ratio of each agent is therefore pivotal to individualize treatment. In fit patients, treatment 
should aim at achieving response, since there is evidence that even among elderly relapsed and/or 
refractory MM (RRMM) patients, the achievement of CR significantly prolongs OS.60 In frail patients 
the major goal of treatment is preserving QoL and minimize toxic complications.31 Unfortunately, 
data on GA in RRMM patients are lacking and there is currently limited evidence on how to adapt 
treatment intensity other than using clinical judgment. Here, we describe the results of selected trials 
in RRMM patients assessing regimen features that can be relevant in elderly patients (Table 5). 
 
Carfilzomib 
In the ENDEAVOR study patients who were not refractory to PIs were randomized to receive either 
carfilzomib-dexamethasone (Kd) or bortezomib-dexamethasone (Vd).61 Median age was 65 years, 
and 15.4% of patients was >75 years of age. In the overall population, Kd led to a clinically 
meaningful prolonged PFS compared to Vd (median PFS 18.7 vs. 9.4 months, respectively; HR 0.53, 
95% CI 0.44-0.65) and this advantage was evident also in patients ≥75 years (HR 0.38, 95% CI 0.23-
0.65). Treatment discontinuation due to AEs was similar in the Kd vs. Vd group (14% vs. 15.7%). A 
lower PNP incidence was reported in the Kd group, while this adverse event frequently led to 
treatment discontinuation in the Vd group. Yet, higher grade ≥ 3 hypertension, dyspnea and cardiac 
failure rates were reported with Kd compared to Vd.  
In the ASPIRE study, patients who were neither refractory to bortezomib nor lenalidomide were 
randomized to carfilzomib-lenalidomide-dexamethasone (KRd) or Rd alone. Median age was 64 
years (12.1% were ≥75 years). KRd induced a longer PFS compared with Rd (median PFS: 26.3 vs 
17.6 months respectively; HR 0.69, 95% CI 0.57-0.83), this benefit was also maintained in patients 
≥75 years (median PFS: 30.3 vs. 16.6 months, respectively; HR 0.62, 95% CI 0.36-1.08).62,63 In the 
safety analysis according to age, the rates of grade ≥3 cardiovascular AEs (hypertension, heart 
failure, ischemic heart disease, pulmonary embolism), neutropenia and thrombocytopenia were 
higher among patients ≥70 years vs. younger patients, and so was also the rate of carfilzomib 
discontinuation due to cardiovascular AEs (6.8% vs. 1.4%). 
 
Ixazomib 
The oral PI ixazomib has been tested in combination with Rd (IRd) vs. Rd in RRMM patients who 
were not refractory to PIs and lenalidomide.64 Median PFS in the IRd group was 20.6 vs. 14.7 months 
in the Rd group (HR 0.74, 95% CI 0.59-0.94). A trend toward an advantage of IRd compared to Rd 
was reported also in 15% of enrolled patients aged ≥75 years (median PFS: 18.5 vs. 13.1 months; 
HR 0.87, 95% CI: not reported). A subgroup analysis revealed that patients with high-risk 
cytogenetics did benefit from IRd vs. Rd (median PFS: 21.4 vs. 9.7 months; HR 0.54, 95% CI 0.32-
0.92) although the cutoff points for defining the presence of high-risk abnormalities were lower 
compared to other trials (5% positive cells for del(17p), 3% positive cells for t(4;14),3% positive cells 
for t(14;16)). Grade ≥3 thrombocytopenia (19% vs. 9%) and diarrhea (6% vs. 3%) were higher with 
IRd, but toxicities were manageable and led to treatment discontinuation in only <2% of patients. 
 
Daratumumab 
The anti-CD38 moAb daratumumab as single-agent was tested in two trials in heavily pretreated 
RRMM patients.65,66 ORR ranged from 29% to 36% and median PFS from 3.7 to 5.6 months in the 
overall population. The drug was well-tolerated and the only safety concern was represented by 
infusion-related reactions (IRRs) (ranging from 42 to 71%), which were manageable and rarely 
severe. The number of elderly patients enrolled was low and overall in the 2 trials only 16 patients 
with ≥75 years could be evaluated for response. The ORR of these elderly patients was 25%, which 
was comparable to the overall population. 
In the POLLUX trial, RRMM patients (not refractory to lenalidomide) were treated with Rd with or 
without daratumumab (Dara-Rd vs. Rd).67 Dara-Rd showed a significantly better PFS as compared 
with Rd (HR 0.37, 95% CI 0.27-0.52). This benefit was even more pronounced in elderly patients 
(≥75 years: HR 0.11, 95% CI 0.02-0.51). AEs leading to treatment discontinuation were limited and 
comparable between treatment groups (6.7% and 7.8% with Dara-Rd vs. Rd, respectively). Higher 
rates of neutropenia, diarrhea, fatigue, nausea, and dyspnea were reported in the Dara-Rd group, 
however they were clinically manageable. IRRs were usually limited to the first infusion and improved 
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with inclusion of the leukotrien antagonist Montelukast. 
In the CASTOR trial, RRMM patients (not refractory to bortezomib) were treated with Dara-Vd vs. 
Vd. Dara-Vd showed an improved PFS (HR 0.39, 95% CI 0.28 to 0.53).68 The Dara-Vd advantage 
was consistent in patients ≥65 years (HR 0.35, 95% CI 0.22 to 0.57), whereas no data are available 
on older patients. No difference in treatment discontinuation due to AEs was reported between Dara-
Vd vs. Vd. Dara-Vd led to a higher rate of hematological toxicity (thrombocytopenia, neutropenia, 
lymphopenia). IRRs were reported in 45%, almost all occurring during the first infusion and rarely 
being severe (≥3 grade: <10%). 
The combination of daratumumab with pomalidomide plus low-dose dexamethasone (Pd) has been 
explored in the phase 1 EQUULEUS study in RRMM patients.69 ORR was 60% and median PFS 
was 8.8 months. No differences in ORR were noted in patients younger or older than 65 years of 
age. The incidence of grade ≥ 3 neutropenia was 78%, however the rate of infections was quite 
similar to published data on Pd alone.70 
 
Elotuzumab 
The anti-SLAMF1 moAb elotuzumab was evaluated in the phase 3 ELOQUENT-2 trial.71 RRMM 
patients (not refractory to lenalidomide) were randomized to elotuzumab-Rd (Elo-Rd) vs. Rd. 
Notably, 20% of patients were ≥75 years. Median PFS with Elo-Rd vs. Rd was 19.4 vs. 14.9 months, 
respectively (HR 0.70, 95% CI 0.57-0.85). Elotuzumab was very well tolerated and IRRs were rare 
and mild. Lymphocytopenia was the only AE, occurring significantly more frequently in the Elo-Rd 
vs. Rd group and leading to an increased incidence of herpes zoster reactivation but no other 
opportunistic infections. No efficacy data are available in patients ≥75 years, however the benefit of 
Elo-Rd was confirmed in ≥65 year-old patients (HR 0.65, 95% CI 0.50–0.85). 
A smaller phase 2 randomized trial also evaluated the combination Elo-Vd vs. Vd, showing a trend 
for a better PFS with Elo-Vd (HR 0.72, 95% CI 0.49-1.06), with similar results between patients ≥65 
years and the overall population.72 
 
Pomalidomide 
The IMID drug pomalidomide combined with dexamethasone was compared to high-dose 
dexamethasone in heavily pretreated RRMM patients. More than 90% of enrolled patients were 
refractory to lenalidomide and 75% were refractory to lenalidomide and bortezomib. Pd significantly 
prolonged PFS (median PFS 4 vs. 1.9 months, HR 0.48, 95% CI 0.39–0.60) and OS (median OS 13 
vs 8 months, HR 0.74, 95% CI 0.56-0.97). Patients receiving Pd, either younger or older than 65 
years, showed similar PFS (3.9 and 4 months, respectively). The analysis of patients aged ≥ 75 
years was limited by the low numbers of patients (24/302 in the Pd arm). The main grade ≥3 AEs 
included neutropenia (48%), infections (34%) and anemia (33%).70 
The addition of oral cyclophosphamide to Pd, particularly in lenalidomide-refractory RRMM patients, 
prolonged median PFS compared to Pd (9.5 vs. 4.4 months, HR 0.54; 95% CI 0.29-1.00). A slight 
increase of myelosuppression was observed with the addition of cyclophosphamide, although not 
significant. No data in subgroups by age were available.73 
 
Recommendations. Trials specifically designed for elderly RRMM patients are lacking and only ~ 
50% of patients enrolled in phase 3 clinical trials are >65 years of age, and ~10-20% of patients 
older than 75 years. Patients with meaningful comorbidities are often excluded from clinical trials, 
leading to a selection bias compared to real life patients and making recommendations in elderly 
patients a challenge.74 The following recommendations are therefore expert-opinion-based, derived 
from subgroup analyses and real life experience.  
In RRMM patients not refractory to PI, Kd is more effective than Vd (1B), however the results reported 
in the control arm might be affected by previous bortezomib treatment. In the same patient population 
Dara-Vd is superior to Vd alone (1B). Thus, PI sensitive patients progressing during or following 
lenalidomide could receive both Kd or daratumumab-Vd. 
In patients who are not refractory to bortezomib and lenalidomide, carfilzomib could be added to Rd, 
if tolerated (2B). Caution is advised when using carfilzomib in elderly patients with pre-existing 
hypertension and cardiac comorbidities (2B). The careful assessment and correction of 
cardiovascular risks and appropriate management of underlying cardiac conditions (cardiac failure 
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and hypertension) need to be ensured before starting carfilzomib treatment. The addition of ixazomib 
to Rd is beneficial in the same patient population (2B).  
In patients not refractory to lenalidomide, and/or progressing during or following bortezomib,  
Daratumumab-Rd or Elo-Rd are recommended over Rd alone (1B).    
Novel combinations do improve but do not overcome high-risk cytogenetics (2B). 
Fit patients may receive full-dose treatments. Intermediate-fit patients may benefit from Elo-Rd or 
Ixazomib-Rd, particularly in non-aggressive relapse (2C). Kd may be an option in patients who have 
no cardiac contraindication and with ensured cardiovascular work-up (1B). Dara-Rd or Dara-Vd may 
be beneficial, without additional toxicity as compared to both doublets Rd and Vd (1B). Among the 
different options, frail patients may benefit from daratumumab, elotuzumab, andixazomib (2C). 
High quality data after third-line therapy in elderly patients are lacking, making it hard to make formal 
recommendations. The expert panel agrees that, in fit elderly patients refractory to lenalidomide and 
PI, Pd,70 Pd plus cyclophosphamide, single-agent daratumumab,65,66 and inclusion in clinical trials 
are reasonable options (2C). In frail patients, low-dose combinations including oral 
cyclophosphamide or melphalan with or without low-dose thalidomide, if tolerated, can help to control 
disease symptoms (2B). 
 
CONCLUSIONS  
Despite recent advances in the treatment of MM patients thanks to novel effective agents, the choice 
of therapy in elderly patients remains a challenge. To make a sensible choice, physicians should 
take into account different fundamental aspects. First, a thorough assessment of patients’ 
characteristics, including age, frailty status, compliance and social support, should be performed. 
Second, disease characteristics are essential to appropriately choose therapy, thus disease stage, 
cytogenetics, tumor burden and aggressiveness of the disease need to be considered. Third, the 
goal of care in the specific patient should be established: whether therapy should aim at achieving a 
deep response (CR and MRD negativity), or disease control (Table 3+4). Finally, drug characteristics 
are crucial: cardiovascular, renal and pulmonary comorbidities, previous PNP and prior 
thromboembolic events are determinant factors in the selection of proper treatment and concomitant 
therapy; moreover, route of administration of a drug - orally, intravenously, subcutaneously - based 
on patient compliance can influence the choice of treatment. A careful GA (Table 2), interdisciplinary 
approaches, and the availability of new, different molecules have provided clinicians with a wide 
variety of possible treatment options, allowing more personalized therapies, with an appropriate 
balance between efficacy and safety.75  
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Table 1. Trials with various new antimyeloma agents in newly diagnosed elderly multiple 
myeloma patients: efficacy and safety 
 
 Schedule 
ORR  
(%) 
PFS  
(months) 
OS  
(mont
hs) 
AEs of interest  
(%) 
MPT vs. MP 
Meta-analysis  
Fayers et al.9 
 
M: 4mg/m2 d 1-7 every 4 weeks for 6 cycles 
or 0.25mg/kg d 1-4 every 6 weeks for 12 
cycles;  
P: 40mg/m2 p.o. d 1-7 every 4 weeks for 6 
cycles or 2mg/kg d 1-4 every 6 weeks for 
12 cycles;  
T: 100mg/d p.o. continuously until PD or 
intolerance or 200mg/d continuously for 12 
cycles of 6 weeks 
59 vs. 
37 
20.3 vs. 
14.9 
39.3 
vs. 
32.7 
- 
MPT vs. MP 
Meta-analysis  
Palumbo et al. 8  
- - - 
Cumulative incidence 
G3-4 hemat: 32 vs. 29 
G3-4 non-hemat: 40 vs. 18 
G3-4 PNP: 6 vs. 1 
MPR-R vs. MPR 
vs. MP 
Phase 3 
Palumbo et al. 19 
9 4-week cycles 
M: 0.18mg/kg  
P: 2mg/Kg d1-4  
R: 10mg/d d 1-21 
Maint. R 10 mg until PD 
77 vs. 
68 vs. 
50 
31 vs. 14 
vs. 13 
 45.2 
vs. NR 
vs. NR 
G3 neutropenia: 67 vs. 64 
vs. 29 
G3 thrombocytopenia: 35 
vs 38 vs. 12 
G3 infection: 9 vs. 13 vs. 7 
VMP vs. MP  
VISTA 
Phase 3 
San Miguel et al. 
10 
9 6-week cycles 
M 9mg/m2 d 1-4 
P 60mg/m2 d 1-4 
V 1.3mg/m2 d1, 4, 8, 11, 22, 25, 29, 32 
cycles 1-4 + d1, 8, 22, 29 cycles 5-9 
71 vs. 
35 
24 vs. 17 
56.4 
vs. 
43.1 
G3-4 PNP: 13 vs. 0 
DARA-VMP vs. 
VMP 
ALCYONE 
Phase 3 
Mateos et al.18  
9 6-week cycles 
Dara 16 mg/kg d 1, 8, 15, 22, 29, 36 cycle 1 
+ d 1, 22 cycles 2-9, every 4 weeks 
thereafter 
 
M 9mg/m2 d 1-4 
P 60mg/m2 d 1-4 
V 1.3mg/m2 d1, 4, 8, 11, 22, 25, 29, 32 
cycle 1 + d1, 8, 22, 29 cycles 2-9 
91 vs 
74 
NR vs 18 
NR in 
both 
arms 
G 3-4 neutropenia: 40 vs. 
39 
 
G 3-4 infections: 23 vs. 15 
 
G 3-4 PNP: 1 vs. 4 
 
G3-4 IRRs: 4 vs. - 
Rd vs. Rd18 vs. 
MPT 
FIRST 
Phase 3 
Benboubker et 
al.14 
4-week cycles 
R: 25mg/d d1-21 
d: 40mg d 1,8,15,22 
 
6-week cycles 
M: 0.25mg/kg d 1-4 
P: 2mg/kg d 1-4 
T: 200mg/d 
75 vs. 
73 vs. 
62 
25.5 vs. 
20.7 vs. 
21.2 
4–yr: 
59% 
vs. 
56% 
vs. 
51% 
G3-4 neutropenia: 28 vs. 
26 vs. 45 
 
G3-4 infections: 29 vs. 22 
vs. 17 
 
G3-4 rash: 6 vs. 5 vs. 5 
VRd vs. Rd  
SWOG-S0777 
Phase 
Durie et al.17 
8 3-week cycles 
V: 1.3mg/m2 d 1, 4, 8,11 
R: 25mg/d d 1-14 
d: 20mg/d d1, 2, 4, 5, 8, 9, 11, 12 
6 4-week cycles 
R: 25mg/d d 1-21 
d: 40mg/d d 1, 8, 15, 22 
82 vs. 
72 
43 vs. 30 
75 vs. 
64 
G≥3 hematol:47 vs. 46 
 
G≥3 neurologic: 33 vs. 11 
KMP vs. VMP  
CLARION 
Phase 3  
Facon et al.16 
7-week cycles 
K: 36mg/m2 IV d 1, 2, 8, 9, 22, 23, 29, 30 
(20mg/m2 d 1, 2, cycle 1 only) over 30 
minutes 
V: 1.3mg/m2 d 1,4,8,11,22,25,29,32 (d 
4,11,25,32 omitted for cycles 5-9) 
M: 9mg/m2 d 1-4 
P: 60mg/m2 d 1-4 
84 vs. 
78 
22 in both 
arms 
NR in 
both 
arms 
G≥3 PNP: <1 vs. 8 
 
G≥3 renal failure: 
7 vs. 2 
G≥3 cardiac failure: 
8 vs. 3 
G≥3 hypertension: 
10 vs. 4 
Abbreviations: ORR: overall response rate; PFS: progression-free survival; OS: overall survival; AEs: adverse events; 
MP: melphalan-prednisone; MPT: melphalan-prednisone-thalidomide; MPR: melphalan-prednisone-lenalidomide; MPR-R: 
melphalan-prednisone-lenalidomide followed by lenalidomide maintenance; VMP: bortezomib-melphalan-prednisone; 
Dara: daratumumab; Rd: lenalidomide-dexamethasone continuously; Rd18: lenalidomide-dexamethasone for 18 courses; 
18 
VRd: bortezomib-lenalidomide-dexamethasone; KMP: carfilzomib-melphalan-prednisone; G: grade; NR: not reached; 
IRRs: infusion related reactions; PNP: peripheral neuropathy; PD: progressive disease; -: not applicable.  
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Table 2. Frailty Assessment in Myeloma 
 IMWG-frailty index31 
Revised  
Myeloma Comorbidity Index32 
Mayo frailty index34 
N 869 801 351 
Median age 74 (46% ≥75) 63 (13% ≥75) 65 (33% ≥75) 
Factors 
Age 
ADL 
IADL 
CCI 
KPS 
Renal function (eGFR) 
Lung (PFTs) 
Fragility 
Age 
+/- Cytogenetics 
Age  
ECOG PS 
NT-Pro-BNP 
Patient 
population 
Selected clinical trial 
patients from 3 studies:  
Rd : MPR : CPR;  
VP : VCP : VMP;  
CCd 
Unselected Unselected 
First-line-
treatment 
Len-based 76% 
PI-based 24% 
SCT: 0% 
Novel-agent-based: 59% 
SCT: 50% 
Len-based 63% 
Bortezomib-based 22% 
ASCT 39% 
Weighted vs. 
unweighted 
score 
Unweighted Weighted Unweighted 
Validation 
assessment 
Non-validated Validated Non-validated 
Access 
www.myelomafrailtyscor
ecalculator.net/ 
www.myelomacomorbidityindex.
org 
- 
Summary 
- Well cited,  
- Well published 
- Generated via test- and 
validation analysis, 
- Compelling statistics, 
- Simple clinical applicability 
- Use of NT-pro-BNP as 
laboratory parameter to add 
risk to performance status and 
age 
 
Abbreviations: IMWG: International Myeloma Working Group; Rd: lenalidomide-dexamethasone; MPR: melphalan-
prednisone-lenalidomide; CPR: cyclophosphamide-prednisone-lenalidomide; VP: bortezomib-prednisone; VCP: 
bortezomib-cyclophosphamide-prednisone; VMP: bortezomib-melphalan-prednisone; CCd: carfilzomib-
cyclophosphamide-dexamethasone; ADL: Activity of Daily Living; IADL: Instrumental Activity of Daily Living; CCI: 
Charlson Comorbidity Index.  
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Table 3. Frailty status definition and related treatment goals in elderly NDMM patients.  
 
IMWG-frailty index: 
Age, CCI, ADL, IADL 
FIT INTERMEDIATE FRAIL 
0 
IMWG-frailty index points 
1 
IMWG-frailty index point 
2-5 
IMWG-frailty index points 
CCI >2: 1 
IADL <5: 1 
ADL <4: 1 
Age 76-80: 1, >80: 2 
R-MCI: 
Age, KPS, renal function, lung function, frailty +/- cytogenetics 
FIT INTERMEDIATE FRAIL 
0-3 
R-MCI points 
4-6 
R-MCI points 
7-9 
R-MCI points 
Age 60-69: 1, >70: 2 
KPS: 80-90%: 2, <70%: 3 
Renal disease: eGFR <60: 1 
Lung disease: moderate/severe: 1 
Frailty: moderate or severe: 1 
+/- cytogenetics: unfavorable: 1 
Mayo frailty index: 
Age, ECOG PS, NT-proBNP 
STAGE I STAGE II STAGE III STAGE IV 
0 
Mayo frailty index 
points 
1 
Mayo frailty index 
point 
2 
Mayo frailty index 
points 
3 
Mayo frailty index 
points 
Age ≥70: 1 
ECOG PS ≥2: 1 
NT-proBNP ≥300 ng/L: 1 
GOAL OF TREATMENT 
FIT INTERMEDIATE FRAIL 
Efficacy: deep response Balance efficacy and toxicity 
Conservative approach, 
low toxicity 
Treatment 
Full-dose therapy 
Full- or reduced-dose 
therapy 
Reduced dose therapy 
ASCT 
 
TRIPLET REGIMENS 
VMP 
VRD 
 
DOUBLET REGIMENS 
Rd 
DOUBLET REGIMENS 
Rd 
Vd 
 
Reduced-dose triplet 
REDUCED-DOSE 
DOUBLET REGIMENS 
rd 
Vd 
 
Palliative + supportive care 
Abbreviations:  
NDMM: newly diagnosed multiple myeloma; ADL: Activity of Daily Living; IADL: Instrumental Activity of Daily Living; CCI: 
Charlson Comorbidity Index; KPS: Karnofsky Performance Status; ECOG PS: ECOG Performance Status; ASCT: 
Autologous Stem Cell Transplantation; R-MCI: revised myeloma Comorbidity Index; VMP: bortezomib-melphalan-
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prednisone; VRD: bortezomib-lenalidomide-dexamethasone; Rd: lenalidomide-dexamethasone; Vd: bortezomib-
dexamethasone. 
 
Table 4. Suggested frailty-adjusted dose reduction in patients with myeloma using standard 
and novel agents 
 
Risk factors 
Age >75 years 
Comorbidities (pulmonary, renal, cardiac and hepatic dysfunction) 
or 
Preferably with a) IMWG-frailty index1 and/or b) R-MCI2 define fit, intermediate-fit and frail patients, in order to 
consider to adapt antimyeloma therapy 
 
Abbreviations: 1 http://195.88.6.191/Frailtyscore/Geriatric.aspx 
2 http://www.myelomafrailtyscorecalculator.net  
 FIT INTERMEDIATE FRAIL 
IMWG-frailty 
index1 
0 1 
 
≥2 
R-MCI2 1-3 4-6 7-9 
DOSE LEVEL 0 -1 -2 
Treatment 
doses 
LEVEL 0 LEVEL -1 LEVEL -2 
Prednisone 
2 mg/kg days 1-4 of a 4-6 
week cycle 
60 mg/m2 days 1-4 of a 6 
week cycle 
1 mg/kg days 1-4 of a 4-6 
week cycle 
30 mg/m2 days 1-4 of a 6 
week cycle 
0.5 mg/kg days 1-4 of a 4-6 
week cycle 
15 mg/m2 days 1-4 of a 6 
week cycle 
Dexamethasone 
40 mg day 1, 8, 15, 22 of a 
28-day cycle 
20 mg day 1, 8, 15, 22 of a 
28-day cycle 
10 mg day 1, 8, 15, 22 of a 
28-day cycle 
Melphalan 
0.25  mg/kg days 1-4 of a 4-
6 week cycle 
0.18  mg/kg days 1-4  of a 4-
6 week cycle 
0.13  mg/kg days 1-4  of a 4-
6 week cycle 
Thalidomide 100 (- 200) mg/day 50 (- 100) mg/day 50 mg qod (- 50mg/day) 
Lenalidomide 
25 mg days 1-21 of a 28-day 
cycle 
15 mg days 1-21of a 28-day 
cycle 
10 mg days 1-21of a 28-day 
cycle 
Pomalidomide* 
4 mg  days 1-21 of a 28-day 
cycle 
3 mg  days 1-21 of a 28-day 
cycle 
2 mg  days 1-21 of a 28-day 
cycle 
Bortezomib 
1.3 mg/m2 twice weekly 
Day 1,4,8,11 every 3 weeks 
1.3 mg/m2 once weekly 
Day 1, 8, 15, 22 every 5 
weeks 
1.0 mg/m2 once weekly 
Day 1, 8, 15, 22 every 5 
weeks 
Carfilzomib°* 
20 mg/m2 d 1, 2, 8, 9, 15, 16 
cycle 1, 27 mg/m2 cycle 2 
every 4 weeks 
20 mg/m2 cycle1 -> 27mg/m2 
cy2, d 1, 8, 15, once weekly 
every 4 weeks 
20 mg/m2 d 1, 8, 15, once 
weekly every 4 (5) weeks 
Ixazomib* 
4 mg d 1,8,15, every 4 
weeks 
3 mg d 1,8,15, every 4 
weeks 
2.3 mg d1,8,15, every 4 
weeks 
Daratumumab* 
16 mg/kg bw cy 1-8: weekly; 
cy9-24: d1+15; week 25 
onwards: every 4 weeks 
16 mg/kg bw cy 1-8:weekly; 
cy9-24: d1+15, week 25 
onwards: every 4 weeks 
 
Consider splitting the dose 
on 2 consecutive days in the 
first cycle. 
16 mg/kg bw cy 1-8:weekly; 
cy9-24: d1+15, week 25 
onwards: every 4 weeks 
 
Consider splitting the dose 
on 2 consecutive days  in 
the first cycle. 
Elotuzumab* 
10 mg/kg bw d 1,8,15,22, cy 
1+2, cy 3: d 1+15 
10 mg/kg bw d 1,8,15,22, cy 
1+2, cy3: d 1+15 
10mg/kg bw d1,8,15,22 cy 
1+2, cy 3: d1+15 
Panobinostat* 
20 mg d1,3,5,8,10,12 every 
4 weeks 
15 mg d1,3,5,8,10,12 every 
4 weeks 
10 mg d1,3,5,8,10,12 every 
5 weeks 
22 
qod: every 2.day; cy: cycle, d: day, bw: body weight; *:no known dose adaptation in elderly and/or frail patients were 
reported. °Carfilzomib dose in the ENDEAVOR study was 56 mg/m2 weekly. No dose modification according 
to age were reported.  
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Table 5. Selected phase 3 trials in RRMM patients 
 
Trials 
ENDEAVOR  
(Kd vs. 
Vd)61 
ASPIRE  
(KRd vs. Rd) 
62,63 
TOURMALIN
E-MM1  
(IRd vs. Rd)64 
CASTOR 
(Dara-Vd vs. 
Vd)68 
POLLUX 
(Dara-Rd vs. 
Rd)67 
ELOQUENT-2 
(Elo-Rd vs. Rd)71 
Median age 
(range) 
65 (30-89) 64 (31-91) 66 (30-90) 64 (30-88) 65 (34-89) 66 (37-91) 
Patients  ≥75 
years (%) 
15.4% 12.1% 15% 11.6% 11.2% 20% 
Key inclusion 
Criteria 
1-3 prior 
lines, 
PI refractory 
excluded 
1-3 prior lines, 
Bor and Len 
refractory 
exlcuded 
1-3 prior lines, 
PI and Len 
refractory 
excluded1 
≥1 prior line, 
primary 
refractory and 
PI refractory 
excluded 
≥1 prior line, 
primary 
refractory and 
Len refractory 
excluded 
1-3 prior lines, 
Len refractory 
excluded 
ORR (%) 77% vs. 63% 87% vs. 67% 78% vs. 72% 83% vs. 63% 93% vs. 76% 79% vs. 66% 
Median PFS 
(months) 
18.7 vs. 9.4 
 
HR 0.53 
(95% CI, 
0.44–0.65) 
26.3 vs. 17.6 
 
HR 0.69 (95% 
CI, 0.57-0.83) 
20.6 vs. 14.7 
 
HR 0.74 (95% 
CI, 0.59-0.94) 
 
NR vs. 7.2 
 
HR 0.39 (95% 
CI, 0.28-0.53) 
NR vs. 18.4 
 
HR 0.37 (95% 
CI, 0.27-0.52) 
19.4 vs. 14.9 
 
HR 0.70 (95% CI, 
0.57-0.85) 
HR in patients 
≥75 years 
HR 0.38 
(95% CI, 
0.23-0.65) 
HR 0.62 (95% 
CI, 0.36-1.08) 
HR 0.87 (95% 
CI not 
reported)2 
NA. In patients 
with ≥65 years  
HR 0.35 (95% 
CI 0.22-0.57) 
HR 0.11 (95% 
CI, 0.02-0.51) 
NA. In patients 
with ≥65 years  
HR 0.65 (95% CI 
0.50-0.85) 
Grade ≥3 
Haematological 
AEs  
Anemia  
14% vs. 10% 
 
Neutropenia 
2% vs. 2% 
 
Thromocytop
enia  
8% vs. 9% 
 
Anemia  
18% vs. 17% 
 
Neutropenia  
30% vs. 26% 
 
Thrombocytop
enia 17% vs. 
12% 
Anemia  
9% vs. 13% 
 
Neutropenia 
23% vs. 24% 
 
Thrombocytop
enia  
19% vs. 9% 
Anemia 
14% vs. 16% 
 
Neutropenia 
13% vs. 4% 
 
Thrombocytop
enia 45% vs. 
33% 
 
Lymphopenia 
10% vs. 3% 
Anemia 
12% vs. 20% 
 
Neutropenia 
52% vs. 37% 
 
Thrombocytope
nia 
13% vs. 13% 
 
Lymphopenia 
5% vs. 4% 
Anemia  
19% vs. 21% 
 
Neutropenia 34% 
vs. 44% 
 
Thrombocytopeni
a 19% vs. 20% 
 
Lymphopenia 
77% vs. 49% 
Grade ≥3  
Non-
haematological 
AEs 
Pneumonia 
7% vs. 8% 
 
Hypertension 
9% vs. 3% 
 
PNP (G≥2) 
6% vs. 32% 
 
Cardiac 
failure 
5% vs. 2% 
Hypokalemia 
9% vs. 5% 
 
Dyspnea 
3% vs. 2% 
 
Hypertension 
4% vs. 2% 
 
Cardiac failure 
4% vs. 2% 
Diarrhea  
6% vs. 3% 
 
Rash  
5% vs. 2% 
 
PNP  
2% vs. 2% 
Pneumonia 
8% vs. 10% 
 
PNP 
5% vs. 7% 
 
Diarrhea 
4% vs. 1% 
 
Hypertension 
7% vs. 1% 
 
Infusion 
related 
reaction 
9% vs. NA 
 
Pneumonia  
8% vs. 8% 
 
Fatigue 
6% vs. 3% 
 
Dyspnea 
3% vs. 1% 
 
Infusion related 
reaction  
5% vs. NA 
 
Diarrhea 
5% vs. 4% 
 
Infusion related 
reaction  
1% vs. NA 
Abbreviations. 1: primary refractory patients included; 2: median progression-free-survival 18.5 vs 13.1 months in patients 
with ≥75 years; G: grade; PI: proteasome inhibitors; KD: carfilzomib-dexamethasone; VD: bortezomib-dexamethasone; 
KRD: carfilzomib-lenalidomide-dexamethasone; RD: lenalidomide-dexamethasone; IRD: ixazomib-lenalidomide-
dexamethasone; Dara-RD: daratumumab- lenalidomide-dexamethasone; Dara-VD: daratumumab-bortezomib-
dexamethasone; Elo-RD: elotuzumab-lenalidomide-dexamethasone; PNP: peripheral neuropathy; NA: not available; NR: 
not reached; Bor: Bortezomib; Len: lenalidomide. 
